Lung Cancer | Tumor

CURE’s Top Stories: January 2021

February 1st 2021, 9:57pm


Each month, we take a look back at the most popular CURE® stories. Here are the top five stories for January 2021.

‘Saved by the Bell’ Actor Dustin Diamond Dies Weeks After Lung Cancer Diagnosis

February 1st 2021, 7:52pm


Dustin Diamond, known best for his role as “Screech” in “Saved by the Bell,” has died after receiving a stage 4 lung cancer diagnosis a few weeks ago.

Decreased Funding Due to the COVID-19 Pandemic Has Negative Impact on Lung Cancer Patient Advocacy and Support Organizations

February 1st 2021, 4:00pm


Despite offering an increased number of services to patients, the decrease in funding as a result of the pandemic has put a strain on patient advocacy and support organizations around the world, leaving many, particularly those that specialize in the support of patients with lung cancer, in urgent need of financial support to continue to meet the increased need.

Long-Term Follow-Up Shows Keytruda Continues to Improve Survival in Patients With PD-L1–Positive Advanced NSCLC

February 1st 2021, 2:00pm


Keytruda monotherapy continued to significantly improve overall and progression-free survival in patients with previously treated, PD-L1–positive advanced non-small cell lung cancer.

Onivyde Shows Promise in Patients with Small Cell Lung Cancer Who Become Resistant to Chemotherapy

January 31st 2021, 3:00pm


Onivyde may offer patients with small cell lung cancer whose disease has progressed after initial chemotherapy a new treatment option, according to updated study results.

Immunotherapy May Be More Beneficial in Treating Small Cell Lung Cancer

January 30th 2021, 3:00pm


Treatment with immuno-oncology therapies induces better responses in younger patients with small cell lung cancer, compared to older patients.

Potential New Treatment Option Shows Promise in Advanced Small Cell Lung Cancer When Combined with Single Agent Chemotherapy

January 29th 2021, 10:00pm


Though there are currently few approved treatments for advanced, pre-treated small cell lung cancer (SCLC), this patient population may have a safe and effective new option in apatinib, according to updated data from a prospective phase 2 study.

Novel Therapy in Combination With Opdivo Shows Promise for Lung Cancer Subset

January 29th 2021, 7:00pm


Treatment with Opdivo (nivolumab) in combination with the novel therapy BMS-986012 demonstrated a median overall survival of 18.7 months and a median progression-free survival of 2.1 months among a group of patients with relapsed/refractory small cell lung cancer.

Patients With Lung Cancer May Need More Support, Education When Making Treatment Decisions

January 29th 2021, 2:00pm


In a survey conducted by the Cancer Support Community, 33% of patients with lung cancer reported they were somewhat or not at all involved in the decision-making process, and 66% were not as knowledgeable about their treatment options as needed to make this decision.

How Biomarkers Impact Treatment Decisions in Lung Cancer

January 28th 2021, 10:00pm


Biomarkers play an important role in treatment decisions of many tumors, but in lung cancer they are a deciding factor between which immunotherapy is the best option.